PULIKE(SH:603566) Shang Hai Zheng Quan Bao·2025-12-02 18:54Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., plans to acquire a 4.04% equity stake in Zhongpu Biological Pharmaceutical Co., Ltd. from CITIC Agriculture Technology Co., Ltd. This acquisition aims to gain control over Zhongpu Biological and improve its operational efficiency and sustainable development capabilities [2][4][5]. Transaction Overview - The transaction does not constitute a related party transaction or a major asset restructuring. It has been approved by the company's board of directors and does not require shareholder approval [3][4]. - The stake being acquired corresponds to an assessed value of 17.5143 million yuan, with the company having a priority purchase right upon the agreement of other shareholders [4][6]. Counterparty Information - CITIC Agriculture is a non-listed joint-stock company with a registered capital of approximately 11.14 billion yuan, established on December 15, 2014. It operates independently from the company in terms of assets and liabilities [5][6]. Target Asset Information - The target asset for this transaction is the 4.04% equity stake in Zhongpu Biological, which is free from any encumbrances or legal disputes [6][7]. - Zhongpu Biological was established in June 2018 with a registered capital of 432.72 million yuan, primarily engaged in the production and sale of veterinary vaccines [7]. Valuation and Pricing - The valuation of the equity stake was conducted by Beijing Zhongqi Hua Asset Appraisal Co., Ltd., using both asset-based and market approaches, with the market approach being favored for its objectivity and relevance to current market conditions [8][9]. Impact on the Company - If the transaction is completed, the company will gain control over Zhongpu Biological, which aligns with its strategic development goals and benefits shareholder interests. The transaction is not expected to lead to management changes or non-operational fund occupation by major shareholders [9].